赛妥珠单抗市场规模、份额和成长分析：按治疗适应症、给药途径/剂型、最终用户和地区划分－2026年至2033年产业预测

2024 年全球 certolizumab pegol 市值为 346 亿美元，预计到 2025 年将成长至 380.6 亿美元，到 2033 年将成长至 815.8 亿美元，在预测期（2026-2033 年）内复合年增长率为 10.0%。

全球赛妥珠单抗市场的主要驱动力是自体免疫疾病盛行率的不断上升，以及对现有生物製药不耐受或无反应的患者对有效治疗方法的需求。该市场涵盖品牌生物製药的销售、医院处方以及针对类风湿性关节炎、克隆氏症、中轴型脊椎关节炎和斑块型干癣等疾病的扩展适应症。赛妥珠单抗独特的药理特性增强了临床医生对其用于治疗育龄妇女的信心，进一步推动了市场需求。类风湿性关节炎覆盖范围和适应症的扩大导致处方量增加，尤其是在类风湿性关节炎和中轴型脊椎关节炎。此外，在偏远地区使用预填充式注射器有助于提高农村地区的用药依从性，而来自生物相似药的预期竞争可能会加速新兴市场的渗透。

全球赛妥珠单抗市场成长要素

随着自体免疫疾病的日益增多，针对慢性发炎路径特异性生物目标製剂的临床需求显着增长，这使得人们对塞妥珠单抗聚乙二醇酯（certolizumab pegol）作为一种有效治疗选择的兴趣日益浓厚。这种持续的临床需求促使医疗系统和医护人员将已上市的生物製药纳入治疗通讯协定，从而推动了处方量的增加，并促使生产商加大对生产和药品获取途径的投入。此外，患者权益倡导和认知水平的提高增强了这些治疗方法的接受度，而临床经验的积累和公认的治疗益处也增强了临床医生的信心；所有这些因素共同推动了塞妥珠单抗聚乙二醇酯市场的稳步增长。

全球赛妥珠单抗市场面临的限制因素

除了生物製药的高昂成本外，不一致的报销政策仍然是限制患者获得赛妥珠单抗聚乙二醇酯（certolizumab pegol）的一大挑战，最终阻碍了市场成长。付款者通常会实施严格的用药控制并限制处方药清单，从而降低了处方柔软性，迫使医疗服务提供者探索替代治疗方法。这些准入障碍阻碍了产品的推广，导致分销网络扩张受阻，并促使生产商制定方案来解决价格承受能力问题。因此，成本敏感性和不均衡的保险覆盖体系共同阻碍了赛妥珠单抗聚乙二醇酯的广泛应用，并限制了市场的整体成长潜力。

全球赛妥珠单抗市场趋势

全球赛妥珠单抗市场正经历重大变革时期，生物相似药竞争日益激烈，重塑发炎性疾病的治疗格局。随着新参与企业推出生物相似药，原厂药生产商正透过提供全面的服务、病患支持倡议以及可靠的生命週期证据来强化自身市场地位，从而实现差异化竞争。支付者和医疗服务提供者越来越重视评估生物相似药在原厂药之外的治疗价值，而临床医生则更关注互通性和临床支持等因素。这种不断变化的竞争格局正在加速客製化进入策略和策略联盟的采用，凸显了真实世界疗效和以患者为中心的益处对于维持市场地位的重要性。

目录

介绍

• 调查目的
• 市场定义和范围

调查方法

• 研究过程
• 二级资料和一级资料的方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争环境概述

市场动态及展望

• 总体经济指标
• 促进者和机会
• 抑制因素和挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

关键市场分析

• 关键成功因素
• 影响市场的因素
• 主要投资机会
• 生态系测绘
• 2025年市场魅力指数
• PESTLE分析
• 监理情势

全球赛妥珠单抗市场规模：依治疗适应症划分

• 克隆氏症
• 类风湿性关节炎
• 干癣性关节炎
• 僵直性脊椎炎
• 斑块型干癣

全球赛妥珠单抗聚乙二醇市场规模：依给药途径/剂型划分

• 预填充式注射器（200毫克）
• 用于復溶的冷冻干燥粉末
• 自动注射器（Cimzia/Cimzia Starter）

全球赛妥珠单抗聚乙二醇市场规模：依最终用户划分

• 专科诊所（风湿病科、消化系统疾病科）
• 住院医院
• 专业零售药房

全球赛妥珠单抗聚乙二醇市场规模：依地区划分

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太国家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲国家

竞争资讯

• 前五大公司对比
• 主要企业2025年的市场定位
• 主要市场公司采取的策略
• 近期市场趋势
• 企业市场占有率分析，2025 年
• 主要企业的完整公司简介
  • 公司详情
  • 产品系列分析
  • 按细分市场进行企业市占率分析
  • 销售收入年比比较（2023-2025 年）

主要企业简介

• UCB SA
• Pfizer Inc.
• AbbVie Inc.
• Amgen Inc.
• Bristol Myers Squibb
• Celgene Corporation
• Genentech, Inc.
• Sanofi SA
• Johnson & Johnson
• Merck & Co., Inc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Regeneron Pharmaceuticals, Inc.
• Nova Biomedical Corporation
• Biogen Inc.
• Mitsubishi Tanabe Pharma Corporation
• Astellas Pharma Inc.
• GSK（GlaxoSmithKline）
• Sandoz International GmbH
• Alnylam Pharmaceuticals, Inc.

结论与建议

Global Certolizumab Pegol Market size was valued at USD 34.6 Billion in 2024 and is poised to grow from USD 38.06 Billion in 2025 to USD 81.58 Billion by 2033, growing at a CAGR of 10.0% during the forecast period (2026-2033).

The global market for certolizumab pegol is primarily driven by the increasing incidence of autoimmune diseases and the need for effective treatments for patients who cannot tolerate or respond to existing biologics. This market encompasses sales of branded biologics, hospital prescriptions, and expanding indications for conditions like rheumatoid arthritis, Crohn's disease, axial spondyloarthritis, and plaque psoriasis. Certolizumab pegol's unique pharmacologic profile enhances clinician confidence in treating women of childbearing age, further boosting demand. Improved payer coverage and expanded labeling have led to increased prescription volumes, particularly in rheumatoid and axial spondyloarthritis. Additionally, remote administration via prefilled syringes fosters adherence in rural areas, while anticipated biosimilar competition may enhance market penetration in emerging economies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Certolizumab Pegol market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Certolizumab Pegol Market Segments Analysis

Global certolizumab pegol market is segmented by therapeutic indication, administration/dosage form, end-user and region. Based on therapeutic indication, the market is segmented into Crohn's Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Plaque Psoriasis. Based on administration/dosage form, the market is segmented into Prefilled Syringe (200 mg), Lyophilized Powder for Reconstitution and Autoinjector (Cimzia/Cimzia Starter). Based on end-user, the market is segmented into Specialty Clinics (Rheumatology/Gastro), In-patient Hospital Settings and Specialty Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Certolizumab Pegol Market

The rise in autoimmune disorders has significantly heightened the clinical demand for targeted biologic therapies that specifically target chronic inflammatory pathways, leading to an increased interest in certolizumab pegol as a viable treatment option. This ongoing clinical requirement compels healthcare systems and practitioners to incorporate established biologics into their treatment protocols, facilitating expanded prescribing and prompting manufacturers to invest in production and accessibility efforts. Additionally, heightened patient advocacy and awareness enhance the acceptance of these therapies, while accumulating clinical experience and perceived therapeutic benefits bolster clinician confidence, all of which contribute to the consistent growth of the certolizumab pegol market.

Restraints in the Global Certolizumab Pegol Market

The high expense of biologic therapies, coupled with inconsistent reimbursement policies, presents ongoing challenges that limit patient access to certolizumab pegol, ultimately hindering market growth. Payers often implement strict utilization controls and place restrictions on formularies, reducing prescribing flexibility and forcing healthcare providers to explore alternative treatment options. These barriers to access diminish product uptake, create reluctance towards expanding distribution networks, and drive manufacturers to develop programs aimed at addressing affordability issues. Consequently, the combined effects of cost sensitivity and uneven coverage frameworks impede widespread adoption and restrict the overall growth potential of the certolizumab pegol market.

Market Trends of the Global Certolizumab Pegol Market

The Global Certolizumab Pegol market is experiencing a significant shift driven by the increasing competition from biosimilars, which is reshaping the landscape of therapeutic options for inflammatory conditions. As new entrants introduce biosimilar products, original manufacturers are responding by enhancing their differentiation through comprehensive service offerings, patient support initiatives, and robust lifecycle evidence to bolster their market presence. Payers and healthcare providers are placing greater emphasis on evaluating therapeutic value beyond the originator's product, while clinicians prioritize factors such as interchangeability and clinical support. This evolving competitive environment accelerates the adoption of customized access strategies and strategic collaborations, underscoring the need for real-world outcomes and patient-centric advantages to maintain market positioning.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Certolizumab pegol Market Size by Therapeutic Indication & CAGR (2026-2033)

• Market Overview
• Crohn's Disease
• Rheumatoid Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Plaque Psoriasis

Global Certolizumab pegol Market Size by Administration/Dosage Form & CAGR (2026-2033)

• Market Overview
• Prefilled Syringe (200 mg)
• Lyophilized Powder for Reconstitution
• Autoinjector (Cimzia/Cimzia Starter)

Global Certolizumab pegol Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Specialty Clinics (Rheumatology/Gastro)
• In-patient Hospital Settings
• Specialty Retail Pharmacies

Global Certolizumab pegol Market Size & CAGR (2026-2033)

• North America (Therapeutic Indication, Administration/Dosage Form, End-User)
  • US
  • Canada
• Europe (Therapeutic Indication, Administration/Dosage Form, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutic Indication, Administration/Dosage Form, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutic Indication, Administration/Dosage Form, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutic Indication, Administration/Dosage Form, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• UCB S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nova Biomedical Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK (GlaxoSmithKline)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations